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Editorials
dis-possessed, the dis-rupted and those with dis-a
systems.
Displaced persons and migrants accounted for 
1201 TB cases in Australia in 2006.7 Overseas-bor
commonly come from India, Vietnam, Indonesia, C
Philippines. Sudan and Somalia have more recently jAustralia, like other high-income countries with a low TB incidence, faces special challenges in controlling TBoo
Th
puB ks with optimistic titles such as Triumph over tuberculosis,e retreat of tuberculosis and The miracle of empty beds wereblished in the 1970s and 1980s. Readers of the Journal
may therefore be surprised to find six articles on tuberculosis (TB)
in this one issue in 2008.1-6 Far from having dis-appeared, TB is






following the shift in Australia’s immigration policy to accept more
African refugees. These national figures are reflected in the letter
from Robinson et al (page 190), which describes a retrospective
review of TB cases seen at The Children’s Hospital at Westmead,
Sydney, between 2004 and 2006.5 Of the 23 children with active
TB disease, 18 (73%) were born overseas, mainly in Africa and the
Indian subcontinent. Compared with data from 1982–1991, the
proportion and number of latent TB infections diagnosed in
children had increased due to active screening of refugee popula-
tions. The article by Dobler et al (page 153) highlights the success-
ful outcome of directly observed treatment for TB cases in
Australia, while alerting Australian doctors to the fact that
migrants with treated TB who visit their TB-endemic country of
birth may develop a second episode of TB that represents a new
infection rather than a relapse of their previous disease.1
TB also affects the disadvantaged and dispossessed, as illustrated
by the fact that the TB incidence in Australia’s Indigenous popula-
tion has been 7–15 times higher than in the non-Indigenous
Australian-born population over the past decade.7
TB affects those with disabled immune systems. People infected
with HIV have nearly 10 times the lifetime risk of developing TB
compared with HIV-negative people.8 HIV/TB coinfection is not
considered a major problem in Australia, with only 11 HIV/TB
patients identified in 2006.7 However, the national TB notification
system recorded the HIV status of only 35.2% of TB patients in
2006.7 Emerson and Post (page 162) rightly exhort Australian
clinicians to offer HIV testing to all TB patients.2 In fact, establish-
ing the HIV status of TB patients could be regarded as an expected
standard of care.
Other immunocompromising conditions — such as chronic
renal failure, transplantation, or treatment with glucocorticoids or
tumour necrosis factor α inhibitors — also increase the risk of TB
reactivation twofold or more.8 For patients about to receive
tumour necrosis factor α inhibitor therapy, Gupta et al (page 168)
propose a screening strategy for latent TB infection using an
interferon γ  release assay, such as QuantiFERON-TB Gold (Cellestis,
Melbourne, Vic) or T-SPOT.TB (Oxford Immunotec, Oxford, UK).6
The optimal application and interpretation of these assays is
controversial. For example, although various versions of the
QuantiFERON assay have been approved by the United States
Food and Drug Administration and endorsed by the US Centers
for Disease Control and Prevention, Australian and Canadian TB
authorities are continuing to recommend the tuberculin skin test
for diagnosing latent TB infections in most patient groups until the
sensitivity, specificity and cost-effectiveness of interferon γ  release
assays have been better defined.9,10
Finally, like many other infectious diseases, TB affects popula-
tions that are disrupted or disorganised due to socioeconomic
upheavals, rapid urbanisation, persistent poverty, conflict or war,
and where public health systems are therefore either weak or non-
existent.11 In a speech to the Lowy Institute in July 2007, Kevin
Rudd (then Federal Opposition Leader) highlighted the “arc of
instability” to Australia’s near north, noting the recent political
unrest in East Timor and several Pacific Island countries and the
continuing impoverishment in parts of Indonesia.12 The link
between TB and this arc of instability is amply demonstrated by
the articles in this issue about illegal foreign fishermen with TB
(page 144)4 and people with multidrug-resistant TB from Papua
New Guinea seeking medical care in the “Torres Strait Protected
Zone” (page 148).3 For example, Gray et al4 estimated the preva-
lence of all TB diagnoses among illegal fishermen screened in
Darwin over a 15-month period to be 1360 cases per 100 000
population!
How should Australia respond internally to this persisting TB
problem? Limiting migration and ostracising migrants is not
indicated, acceptable or practicable in the “global village” of the
21st century. We require migrants and temporary visitors for our
economy, for plugging skill gaps in our workforce, and for nation
building. Moreover, molecular epidemiological studies in Australia
and overseas have demonstrated that there is negligible transmis-
sion of TB from migrant communities to the general popula-
tion.13,14 The appropriate interventions are to optimise pre- and
post-migration detection of active TB disease, to familiarise
migrants with the TB clinical services that are freely available if
they develop disease, and to detect and treat latent TB infections
among subgroups of migrants who would benefit from this
intervention (eg, children under 15 years old).
The 2006 annual report of the National Tuberculosis Advisory
Committee does highlight one migrant subgroup requiring partic-
ular attention by documenting that the number of TB cases among
health care workers (HCWs) has risen from 34 in 2001 to 65 in
2006.7 This rise is attributable to the increasing recruitment of
HCWs from high-incidence TB countries. There were no reports of
TB transmission from HCWs to patients in 2006.7 Nonetheless,
public and private health institutions, particularly those recruiting
HCWs from high-incidence TB countries, must ensure that ade-
quate TB screening is undertaken before and during employment.
In common with other high-income countries with a low TB
incidence, Australia faces special challenges in controlling TB.15
Continuing undergraduate and postgraduate education of medical
and nursing personnel is required to ensure that health profession-
als remember to “think TB” in at-risk patients. Despite the lowMJA • Volume 188 Number 3 • 4 February 2008 131
EDITORIALSincidence of TB, federal and state governments must be encour-
aged to continue funding TB control efforts and must be dissuaded
from devolving TB care from specialised TB services to general
clinics in city hospitals. The closure of specialised TB services
contributed to the TB epidemic in New York City in the 1980s and
1990s, which may ultimately have cost several billion dollars to
control.16 The low incidence of TB may also discourage pharma-
ceutical companies from selling small volumes of anti-TB drugs at
narrow profit margins in Australia, which is a geographically
isolated market with stringent regulatory requirements. Federal
administrators may need to develop novel solutions to ensure
reliable anti-TB drug supplies into the future.
How should Australia respond externally to the persisting
problem of TB? As long ago as 1993, the TB problem was declared
a global emergency requiring a global response. Rudd’s 2007
speech to the Lowy Institute proposed a new strategic partnership
with our northern neighbours that emphasised proactive socio-
economic development and promised an increase in Australia’s
official development assistance (as a percentage of gross national
income).12 TB is one issue for which this rhetoric should become
action. In responding to TB as a global emergency, Australia needs
to provide direct continuing TB care in specific circumstances to
foreign nationals, such as people with multidrug-resistant TB
entering the “Torres Strait Protected Zone” and illegal fishermen
entering Australian waters.3,4 Addressing only “acute life-threaten-
ing conditions” in these groups, as quoted in the article by Gilpin
and colleagues,3 is short-sighted in view of the fact that TB is both
communicable and potentially deadly. A collaborative approach is
necessary in Australia’s border areas.
More generally, Australia’s clinical and laboratory expertise in TB
control could be harnessed to assist with national TB programs in
neighbouring countries through properly funded bilateral partner-
ships. Such collaboration would be to our mutual benefit. Invest-
ment in TB programs in neighbouring high-incidence countries is
one control strategy that has been largely ignored by high-income
countries with low TB incidence. One analysis suggested that US-
funded expansion of TB care into Mexico, Haiti and the Dominican
Republic could reduce TB disease among migrants from these
countries and would produce net savings for the US.17 The authors
suggested that their findings could be generalised to other devel-
oped countries with large migrant intakes and should encourage
those countries to fund TB control efforts abroad. TB really is
where philanthropy and self-interest meet!
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